Oesophageal Cancer: Who Needs Neoadjuvant Therapy?

Lancet Oncol. 2011 Jul 1;12(7):615-616, TN Walsh

Despite having the poorest outcomes of almost all solid tumours, not all surgeons are convinced of the need for, or the benefit of, adjunctive treatment for oesophageal cancer. At the heart of the problem seems to lie an overinterpretation of the published work on the role of surgery. Over 30 years ago, Earlam and Cunha-Melo published the first major overview of the role of surgery for oesophageal cancer, which made for grim reading. Of every 100 patients, 58 were explored, 39 underwent resection,...

NOT A MEMBER?

Registration is FREE

  • Up-to-date oncology news
  • Journal article summaries
  • Commentaries and interviews
  • Drug and interactions database
  • Chemotherapy regimens
  • Daily e-newsletters

 

Section Editor

Dr. David Henry is Section Editor of My Approach.

Meet Our Experts

Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
  • Forgot your password?
    Not a member? Free registration